Chronic Type B Dissection, better with endoprosthesis than with medical treatment

Original title: The results of stent graft versus medication therapy for chronic type B dissection Reference: Xin Jia et al. J Vasc Surg 2013;57:406-14

In many institutions patients with Chronic Stanford Type B Aortic Dissection is most often treated medically, and the thoracic endovascular aortic repair implant TEVAR or the surgical procedure are reserved for those who evolve with complications (persistent pain, expansion of false lumen, visceral or peripheral ischemia). 

Even though these complications may not present, the prognosis for these patients continues to be around 30% mortality at 2 years. This prospective study included 303 consecutive patients with chronic type B aortic dissection that received, following medical criteria, optimal medical therapy (OMT) (95 patients) or thoracic endovascular aorta repair (TEVAR) (208 patients). There were no significant differences in baseline characteristics between the two groups. The median time between dissection and endoprosthesis was 23 days. 

No deaths occurred during index hospitalization in the two groups. The TEVAR group 2 patients (0,9%) required emergency surgery for retrograde type A dissection, 6 patients (2,9%) had vascular complications, 2 patients (0,9%) presented neurological compromise and 2 patients (0,9%) periprocedural infarction. No patients in the OMT group presented events in 30 days.

Conclusion 

This multicenter, prospective and not randomized study, showed lower mortality with TEVAR in treating chronic type B aortic dissection vs. OMT. However, global mortality showed no differences.

Editorial comment

Follow up was lost in more than 20% of patients in both groups but especially in the OMT group (as expected). This makes it difficult to interpret results at long term, precisely when benefits of precocious intervention should be seen. Beyond this limitation, this study shows a very acceptable complications rate at 30 days with the intervention, which raises questions about the efficiency of the traditional management of these patients.

SOLACI.ORG

More articles by this author

Renal Denervation, 24-Month Evolution

Hypertension is a very common condition, and generally manageable. However, as we know, it is associated to cardiovascular events.  Even though the therapeutic arsenal enables...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Watchman FLX and Improvement Impact vs. 2.5

Left atrial appendage occlusion (LAAO) represents an effective alternative to oral anticoagulation (OAC) in patients with non-valvular atrial fibrillation at high risk of thromboembolic...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...